stockrow
Saturday 7 November 2026
Export BCTX’s income statement to Excel — free account
BRIACELL THERAP
BCTX Healthcare Biotechnology
- EPS
- +110.2%
- Free cash flow
- +26.7%
Quarter to July 2026, against a year earlier
4.00
0.73
+22.32%
Follow BCTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.0 pt | ||||||
| EBT | (2) | (4) | (4) | (4) | (14) | (27) | (20) | (5) | (27) | (35) | +34.6% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (2) | (4) | (4) | (4) | (14) | (27) | (20) | (5) | (27) | (35) | +34.6% | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (1,072.06) | (1,490.52) | (1,131.73) | (779.61) | (458.27) | (259.37) | (194.90) | (43.48) | (62.19) | (7.05) | (42.8%) | ||||||
| Cash flow | (635.84) | (1,365.49) | (995.93) | (263.73) | (257.48) | (120.86) | (227.88) | (219.93) | (66.58) | (5.72) | (40.8%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (4.16) | 0.00 | (0.03) | n/m | ||||||
| Free cash flow | (635.84) | (1,365.49) | (995.93) | (263.73) | (257.48) | (120.86) | (227.88) | (224.09) | (66.58) | (5.74) | (40.7%) | ||||||
| Book value | 311.25 | 339.08 | (165.41) | (749.46) | 919.33 | 99.99 | (36.25) | (24.47) | 40.97 | 3.11 | (40.1%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | +135.3% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (4) | (4) | (1) | (8) | (12) | (24) | (24) | (28) | (29) | +39.4% | |||||
| Capex | 0 | — | — | — | — | — | — | 0 | — | 0 | n/m | ||||||
| Free cash flow | (1) | (4) | (4) | (1) | (8) | (12) | (24) | (25) | (28) | (29) | +39.5% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | 1 | 1 | (1) | (4) | 57 | 41 | 25 | (4) | 16 | 14 | +39.5% | |||||
| Net debt | (2) | (1) | 0 | 0 | (57) | (41) | (21) | (1) | (18) | (21) | +33.6% | ||||||
| Shareholders’ equity | 1 | 1 | (1) | (4) | 28 | 10 | (4) | (3) | 17 | 16 | +41.0% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | (205.57) | (219.39) | (317.98) | (860.95) | (47.18) | (53.35) | (58.22) | (29.01) | (191.21) | (154.34) | +51.2 pt | |||||
| ROIC | 0.00 | (754.89) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (329.47) | (509.54) | (2,667.58) | 189.99 | (114.78) | (141.26) | (619.76) | 148.30 | (359.23) | (212.23) | +117.2 pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | 5 | 12 | 12 | 18 | 22 | — | +44.8% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
BRIACELL THERAP vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IRLA IRulya Therapeutics Inc. | $29.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LITS Lite Strategy, Inc. | $29.6M | — (loss-making) | — (loss-making) | +647.96% (above 0%: growing) | n/m | +179.28% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EDSA Edesa Biotech, Inc. | $28.8M | — (loss-making) | — (loss-making) | −99.88% (below 0%: shrinking) | n/m | −81.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BCTX BRIACELL THERAP | $28.6M | — (loss-making) | — | — | n/m | +26.73% (above 0%: growing) | 0.00% | 0.00% | |
| ANVS Annovis Bio, Inc. | $28.6M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | Compare |
| ALGS Aligos Therapeutics, Inc. | $28.2M | — (loss-making) | — (loss-making) | +287.18% (above 0%: growing) | n/m | +105.91% (above 0%: growing) | 100.00% | (762.98%) | Compare |
| MGX Metagenomi Therapeutics, Inc. | $27.6M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | Compare |
| PLRZ Polyrizon Ltd. | $27.5M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| ACET Adicet Bio, Inc. | $27.3M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $28.4M | — | — | +287.18% | — | −27.83% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 12 February 2026
Ownership
Directors and executive officers, together
0.74%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement